Tamoxifen-induced Ghr deletion in SV40 C3(1) T-antigen mouse prostates

Seven-month old tamoxifen-inducible Ghr recombination mice in T-antigen mouse model of prostate cancer (Ghrflox/flox;ROSA26Cre-ERT2+/0;SV40 C3(1) T-antigen+/0) or tamoxifen-control mice (Ghrflox/flox;SV40 C3(1) T-antigen+/0) were treated with 250 mg/kg tamoxifen for five straight days. The dorsolateral prostate of each mouse was collected one month after final treatment and RNA was collected. Samples include 5 samples. Two biological replicates of tamoxifen-control DLPs and three biological replicates of Ghr deletion DLPs.